Hormones After Breast Cancer: What Survivors Need to Know

By Glow Health | Menopause & Sexual Health Specialists

Breast cancer is the most common cancer among women worldwide, and as screening and treatment have improved, more women are living longer after diagnosis than ever before. That is genuinely good news. But it also means that more women are navigating years, sometimes decades, of life after treatment, often in menopause, often with significant symptoms, and often with very little guidance about what hormonal options are available to them.

The default message most breast cancer survivors receive is simple: no hormones, ever. For many women, that message is delivered without nuance, without discussion of what type of cancer they had, what treatment they completed, how long ago it was, or what the current evidence actually shows. It is a blanket prohibition that causes real harm through unnecessary suffering and, for many women, through the downstream health consequences of undertreated menopause.

This post is not an argument that all breast cancer survivors should use hormone therapy. It is an argument that the conversation deserves more than a blanket no, that the evidence is more nuanced than most women are told, and that shared decision-making with a clinician who understands both oncology and menopause medicine is what every survivor deserves.

Why this matters

Breast cancer treatment frequently causes or accelerates menopause. Chemotherapy can damage ovarian function, sometimes permanently. Aromatase inhibitors suppress estrogen throughout the body. Surgical removal of the ovaries, which may be recommended for women with BRCA mutations, causes abrupt surgical menopause. The result is that many breast cancer survivors experience some of the most severe menopausal symptoms of any population, at younger ages than average, and for longer periods.

Hot flashes, sleep disruption, cognitive changes, vaginal dryness, painful sex, urinary symptoms, mood changes, bone loss, and cardiovascular risk changes are all part of this picture. These are not minor inconveniences. They affect quality of life profoundly and, in the case of bone and cardiovascular health, carry real long-term consequences.

At the same time, the stakes of any treatment decision in this population are high. Hormone receptor-positive (HR+) breast cancer, which accounts for approximately two thirds of invasive breast cancers, is driven in part by estrogen signaling. This is a biologically different situation from that of a healthy postmenopausal woman considering hormone therapy, and it requires a different level of caution and individualization.

Understanding your diagnosis matters

Not all breast cancer is the same, and the hormone therapy conversation looks very different depending on the type of cancer a woman had.

Hormone receptor-positive (HR+) breast cancer is sensitive to estrogen and progesterone. Endocrine therapies like tamoxifen and aromatase inhibitors are central to treatment for this reason. The relationship between estrogen and HR+ cancer cells is why systemic hormone therapy requires the most careful individualized consideration in this group.

Hormone receptor-negative (HR-) breast cancer does not rely on estrogen or progesterone signaling for growth. This includes HER2-positive tumors and triple-negative breast cancers. Because these cancers are not hormonally driven, the theoretical concern about estrogen stimulating recurrence is substantially lower. The evidence does not suggest that hormone therapy increases recurrence risk in HR- survivors, and many oncologists are more open to discussing it in this group, particularly for women who are several years beyond treatment completion.

The type of surgery, whether lumpectomy or mastectomy, does not by itself change the hormone therapy conversation for HR+ cancer. What matters is the receptor status, the treatment received, and the time since diagnosis.

The evidence on systemic hormone therapy in survivors

The honest summary of the data is this: the evidence is not definitive in either direction for HR+ survivors, and the absence of large well-powered randomized controlled trials is the central problem.

Two older randomized trials, the HABITS trial and the Stockholm trial, looked at hormone therapy in breast cancer survivors and produced conflicting results. The HABITS trial was stopped early due to a signal of increased recurrence in the hormone therapy group. However, the trial had a significant methodological flaw that fundamentally undermines its conclusions: there was no baseline mammogram requirement before enrollment. This means women may have entered the trial with undetected disease already present. When recurrences appeared within five to ten months of starting hormone therapy, they almost certainly represented pre-existing cancer rather than disease caused by the hormones. The Stockholm trial, which used a different regimen and recruited a different patient population, did not show increased recurrence. Neither study used the modern bioidentical formulations that are standard today, and neither was large enough to draw confident conclusions.

What we do know from studies in healthy postmenopausal women is that estrogen alone, without a progestogen, does not appear to increase breast cancer risk and in the WHI showed a reduction in breast cancer incidence of approximately 8 fewer cases per 10,000 women compared to placebo. The finding that raised concern in the WHI was specifically with the addition of synthetic medroxyprogesterone acetate (MPA) to estrogen therapy. CEE alone, used in women who had undergone hysterectomy, was actually associated with a reduction in breast cancer incidence. The absolute increase was 1 additional case per 1,000 women, and this finding did not quite reach statistical significance. Multiple observational studies and the French E3N cohort have suggested that modern formulations using bioidentical progesterone carry significantly lower or no increased breast cancer risk compared to synthetic progestins.

Whether these findings extrapolate to women who have already had breast cancer is unknown. ER+ breast cancer cells are biologically distinct from normal breast cells, and we cannot assume that what is safe in healthy women is equally safe in survivors. This is the honest clinical reality, and it is why the standard framework remains: non-hormonal options first, with systemic hormone therapy considered through careful individualized shared decision-making.

The question raised in the emerging research community is a fair one: if estrogen alone has never shown increased breast cancer risk, and if modern bioidentical formulations appear more breast-neutral than older synthetic ones, why is the bar so high for survivors? The answer is not that the question is unreasonable. It is that the quality of data in this specific population has not yet caught up with the biological plausibility. Approximately 15% of breast cancer survivors are already using hormone therapy, and that data is largely going uncollected, which is a significant missed opportunity for the field.

Timing matters for HR+ cancer

For women with hormone receptor-positive breast cancer, the timing since diagnosis is clinically relevant. HR+ cancer has a long natural history, with recurrence risk that extends 15 to 20 years beyond diagnosis rather than resolving at the five-year mark. This is an important consideration in any hormone therapy discussion.

Vaginal hormones: a different conversation

Local vaginal hormones, including vaginal estrogen and Intrarosa (prasterone/DHEA), are not the same as systemic hormone therapy and should not be treated as such.

As discussed throughout this blog, vaginal hormones work locally with minimal systemic absorption. They do not meaningfully raise circulating estrogen levels. The evidence does not suggest that vaginal estrogen affects breast cancer survival. A 2023 systematic review and meta-analysis found that prasterone showed no elevation of serum estradiol in breast cancer survivors. Studies specifically examining vaginal estrogen in breast cancer survivors have not shown increased recurrence risk.

Vaginal hormones are safe for all breast cancer survivors. For women on aromatase inhibitors, vaginal estrogen remains appropriate. Because AIs suppress systemic estrogen production, there is a theoretical concern about any additional estrogen exposure, but the evidence does not support withholding local vaginal hormones in this group. The ring formulation (Estring) and suppository or tablet formulations such as Vagifem or Imvexxy have the most safety data in breast cancer survivors and are generally preferred. Estrogen cream applied externally to the vulva, rather than inserted internally with an applicator, is also safe and does not raise the same systemic absorption concerns. Vaginal moisturizers and lubricants remain useful adjuncts for all women in this group.

Intrarosa (prasterone/DHEA) is also a safe and effective option, and a particularly reassuring choice for women who have any residual concerns about local estrogen exposure given its different mechanism of action.

Emerging options worth knowing about

Duavee (conjugated estrogen with bazedoxifene) is an FDA-approved oral estrogen combined with bazedoxifene, a third-generation SERM that acts as an estrogen antagonist specifically in breast and endometrial tissue. Early studies show that Duavee does not increase mammographic breast density, which matters for two reasons: increased density raises breast cancer risk in its own right, and any change in density or breast tenderness following a mammogram is genuinely alarming for survivors. The PROMISE trial, presented at ASCO, found that Duavee actually reduced markers of breast cell proliferation in women with hormone receptor-positive DCIS, cutting Ki-67, a protein that measures how quickly cancer cells are dividing, in half. Duavee is currently being studied for breast cancer prevention in high-risk women. Its use in breast cancer survivors is off-label, and while the data are early and encouraging, it requires individualized discussion and careful clinical judgment. For the right candidate, it represents a potentially meaningful option.

The pregnancy data and what it tells us is also worth noting. The POSITIVE trial, published in the New England Journal of Medicine, followed women with early-stage HR+ breast cancer who interrupted their adjuvant endocrine therapy for up to two years to attempt pregnancy, including IVF with supraphysiologic estrogen exposure. Short-term breast cancer events, recurrence, and mortality did not differ significantly from controls. This does not directly prove that hormone therapy is safe, but it does raise important questions about the consistency of the medical community's position on hormone exposure in this population.

What this means for your care

If you are a breast cancer survivor experiencing significant menopausal symptoms, the most important thing to know is that the conversation does not have to end with a blanket no.

Vaginal symptoms, including dryness, pain during sex, and urinary symptoms, can almost certainly be treated safely with local vaginal hormones regardless of your diagnosis. Non-hormonal options for systemic symptoms, including elinzanetant, SSRIs, SNRIs, and gabapentin, are always available and worth exploring. And for some survivors, particularly those with hormone receptor-negative cancer or those many years beyond treatment completion with HR+ cancer, systemic hormone therapy may be a reasonable option to discuss with a clinician who has expertise in both menopause medicine and oncology.

The evidence in this area is evolving, the data collection is inadequate, and the decisions are genuinely difficult. That is precisely why they deserve a thorough, individualized conversation rather than a reflexive dismissal.

How Glow Health can help

At Glow Health, we are comfortable navigating the intersection of menopause and breast cancer history, and we approach these conversations with the seriousness, nuance, and honesty they deserve. We work collaboratively with oncologists where appropriate, and we help each woman understand her specific situation, the relevant evidence, and her options.

If you are a breast cancer survivor who has been told there is nothing to be done about your symptoms, we would welcome the opportunity to have a more complete conversation.

Keywords: hormone therapy after breast cancer, HRT breast cancer survivors, menopause after breast cancer, vaginal estrogen breast cancer, breast cancer and hormones, estrogen after breast cancer, breast cancer menopause symptoms, hormone positive breast cancer HRT

This post is for informational purposes only and does not constitute medical advice. Please consult a qualified healthcare clinician for personalized guidance.